BlueWind Medical

Executive Summary

BlueWind Medical is a private Israeli med-tech company commercializing Revi, an innovative implantable tibial neuromodulation system for treating urge urinary incontinence (UUI) and overactive bladder (OAB). Unlike traditional sacral neuromodulation or pharmaceutical therapies, Revi offers a minimally invasive, patient-controlled outpatient solution. The device is implanted near the ankle and delivers programmable electrical stimulation to the posterior tibial nerve, providing drug-free symptom relief. The company targets the sizable OAB market, which is underserved by current therapies due to side effects or invasiveness. BlueWind has received CE mark approval and is focusing on European commercialization while pursuing U.S. FDA clearance. With a strong intellectual property portfolio and positive clinical data, the company is positioned for growth, though it faces competition from established players like Medtronic and Axonics. The private nature limits financial visibility, but its commercial stage and clear value proposition suggest reasonable near-term upside.

Upcoming Catalysts (preview)

• Q2 2026FDA Approval for Revi System65% success
• Q3 2026Strategic Partnership for U.S. Distribution50% success
• Q3 2026New Clinical Data Publication75% success